Immunoscoring breast cancer: TILs remember what they target

Ann Oncol. 2014 Aug;25(8):1455-6. doi: 10.1093/annonc/mdu227. Epub 2014 Jun 20.

Authors

G Curigliano¹, E A Perez²

Affiliations

¹ Division of Experimental Therapeutics, Istituto Europeo di Oncologia, Milano, Italy giuseppe.curigliano@ieo.it.
² Division of Hematology/Medical Oncology and Cancer Biology, Mayo Clinic Cancer Center, Mayo Clinic, Jacksonville, FL, USA.

PMID: 24950980
DOI: 10.1093/annonc/mdu227

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Pharmacological*
Biomarkers, Tumor*
Female
Humans
Lymphocytes, Tumor-Infiltrating / pathology*
Triple Negative Breast Neoplasms / drug therapy*
Triple Negative Breast Neoplasms / immunology*

Substances

Antibodies, Monoclonal, Humanized
Biomarkers, Pharmacological
Biomarkers, Tumor